News

The Dose Podcast - Episode 2 "Translating the UNHLM Commitments into Action"

19 Dec 2018
by Working Group
TB Drug R&D Civil Society UN UNHLM advocacy

Episode 2: "Translating the UNHLM Commitments into Action: Ensuring Investment in TB R&D to eliminate TB" 

The second episode of The Dose Podcast will focus on the first ever High-Level Meeting on Tuberculosis held by the United Nations General Assembly and the commitments made there to fight TB. The High-Level Meeting is only the fifth time that the UN in its history has called for a high-level meeting devoted to a health issue.  This podcast will highlight the outcomes resulting from the UNHLM, consider how we can hold countries accountable to their commitments, as well as drive the momentum in development of new TB therapies, vaccines and diagnostics.

Moderator: Bobby Ramakant, Citizen News Service

Speaker: Honorable Nick Herbert, Member of Parliament for Arundel and South Downs in the UK.

Speaker: Blessi Kumar, CEO of the Global Coalition of TB Activists

Listen on Soundcloud: https://soundcloud.com/user-87209407/the-does-podcast-episode-2-translating-the-unhlm-commitments-into-action

More News
22 Jul 2024

With NIH Funding, A New Consortium Aims to Improve TB Treatment

The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024

WHO Released Its Updated Bacterial Priority Pathogens List

On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024

Most Robust TB Drug Pipeline in History

For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...